Leerink Partnrs Brokers Decrease Earnings Estimates for FDMT

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) – Research analysts at Leerink Partnrs dropped their FY2024 earnings estimates for 4D Molecular Therapeutics in a report issued on Wednesday, November 13th. Leerink Partnrs analyst M. Foroohar now expects that the company will post earnings per share of ($2.95) for the year, down from their prior forecast of ($2.84). The consensus estimate for 4D Molecular Therapeutics’ current full-year earnings is ($2.81) per share. Leerink Partnrs also issued estimates for 4D Molecular Therapeutics’ Q4 2024 earnings at ($0.86) EPS and FY2025 earnings at ($3.76) EPS.

Several other analysts have also commented on FDMT. Cantor Fitzgerald lowered 4D Molecular Therapeutics from an “overweight” rating to a “neutral” rating in a research note on Monday, September 23rd. Leerink Partners restated an “outperform” rating and issued a $36.00 target price (down previously from $40.00) on shares of 4D Molecular Therapeutics in a research note on Thursday, September 19th. Royal Bank of Canada lowered their target price on shares of 4D Molecular Therapeutics from $40.00 to $39.00 and set an “outperform” rating on the stock in a report on Thursday, November 14th. Chardan Capital reissued a “buy” rating and set a $39.00 price target on shares of 4D Molecular Therapeutics in a report on Thursday, November 14th. Finally, HC Wainwright restated a “buy” rating and issued a $36.00 price target on shares of 4D Molecular Therapeutics in a research report on Thursday, November 14th. One research analyst has rated the stock with a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $47.00.

4D Molecular Therapeutics Trading Up 4.2 %

FDMT stock opened at $8.67 on Monday. 4D Molecular Therapeutics has a 1-year low of $7.32 and a 1-year high of $36.25. The business’s 50 day moving average is $10.03 and its 200-day moving average is $16.78. The firm has a market cap of $400.80 million, a P/E ratio of -3.04 and a beta of 2.82.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Price T Rowe Associates Inc. MD increased its position in 4D Molecular Therapeutics by 6.0% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 23,952 shares of the company’s stock valued at $764,000 after acquiring an additional 1,356 shares in the last quarter. Principal Financial Group Inc. increased its holdings in shares of 4D Molecular Therapeutics by 9.6% in the second quarter. Principal Financial Group Inc. now owns 21,034 shares of the company’s stock valued at $442,000 after purchasing an additional 1,849 shares in the last quarter. Algert Global LLC increased its holdings in shares of 4D Molecular Therapeutics by 20.6% in the second quarter. Algert Global LLC now owns 16,588 shares of the company’s stock valued at $348,000 after purchasing an additional 2,828 shares in the last quarter. Allspring Global Investments Holdings LLC raised its position in 4D Molecular Therapeutics by 702.1% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 3,457 shares of the company’s stock worth $110,000 after purchasing an additional 3,026 shares during the last quarter. Finally, California State Teachers Retirement System lifted its holdings in 4D Molecular Therapeutics by 12.6% during the 1st quarter. California State Teachers Retirement System now owns 28,490 shares of the company’s stock worth $908,000 after buying an additional 3,197 shares in the last quarter. Institutional investors and hedge funds own 99.27% of the company’s stock.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.